GE HealthCare raises annual profit forecast on smaller tariff impact

GE HealthCare Technologies (GEHC.O) raised its annual profit forecast to $4.43-$4.63 per share, up from $3.90-$4.10, primarily due to a significantly reduced expected tariff impact of 45 cents per share, down from 85 cents. This positive revision, which also includes an updated annual organic revenue growth forecast of 3%, follows a strong second quarter where the company surpassed Wall Street estimates with $5.01 billion in revenue and $1.06 adjusted EPS. The reduced tariff burden is a broader trend benefiting other medical device makers and comes amidst sustained high demand for elective surgical procedures, reinforcing a favorable industry environment.

Analysis

GE HealthCare has issued a significant upward revision to its full-year 2025 profit forecast, increasing the guided range to $4.43-$4.63 per share from a previous $3.90-$4.10. This substantial adjustment is primarily driven by a more favorable outlook on tariffs, with the expected negative impact nearly halved from 85 cents to 45 cents per share. This development places GEHC alongside peers like Boston Scientific and Johnson & Johnson, who have also reduced their tariff cost expectations, signaling a broader sector-wide tailwind from easing trade-related pressures. The optimistic guidance is substantiated by a strong second-quarter performance, where the company exceeded Wall Street estimates with revenue of $5.01 billion and an adjusted EPS of $1.06, beating the consensus of $4.96 billion and 92 cents, respectively. This performance was fueled by growth across all four business units and sustained high demand for elective surgical procedures. Despite these positive indicators, the company's adjusted core margin contracted by 80 basis points during the quarter due to the lingering impact of tariffs, a metric that warrants monitoring. An analyst from J.P. Morgan noted that the new guidance may still be conservative, suggesting potential for further upside.

Key Decisions for Investors

• Investors should view the substantial upward revision in the 2025 EPS forecast as a strong bullish signal, prompting a re-evaluation of valuation models to reflect the new earnings power.
• The easing of tariff pressures is a sector-wide theme, suggesting potential upside not just for GEHC but also for peers; consider a review of overall exposure to the medical device industry.
• While the outlook is positive, attention should be paid to the 80 basis point decline in adjusted core margin, as continued margin pressure could partially offset the benefits from lower tariffs and revenue growth.